Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia

Expert Review of Hematology

Volumn 6, Issue 3, 2013, Pages 255-264

  Breda, Laura ^a   Rivella, Stefano ^a   Zuccato, Cristina ^b   Gambari, Roberto ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

thalassemia; erythroid progenitor cells; gene therapy; hemoglobin; high persistency of fetal hemoglobin; sickle cell anemia

Indexed keywords

HEMOGLOBIN BETA CHAIN; HEMOGLOBIN F; LENTIVIRUS VECTOR; RETROVIRUS VECTOR; THALIDOMIDE; TRANSCRIPTION FACTOR GATA 1;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALPHA THALASSEMIA; BETA THALASSEMIA; BLOOD TRANSFUSION; CHROMOSOME 6Q; CLINICAL TRIAL (TOPIC); ERYTHROPOIESIS; GENE EXPRESSION; GENE LOCUS; GENE REARRANGEMENT; GENE THERAPY; GENETIC TRANSCRIPTION; GENOTOXICITY; HUMAN; IRON CHELATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRAL GENE THERAPY;

ANTISICKLING AGENTS; AZACITIDINE; BETA-GLOBINS; BETA-THALASSEMIA; FETAL HEMOGLOBIN; GENETIC THERAPY; GENETIC VECTORS; HUMANS; HYDROXYUREA; LENTIVIRUS; RETROVIRIDAE; THALIDOMIDE;

EID: 84879400495     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.13.24     Document Type: Review

References (118)

1. Patrinos GP, Kollia P, Papadakis MN. Molecular diagnosis of inherited disorders: lessons from hemoglobinopathies. Hum. Mutat. 26(5), 399-412 (2005).
2. Old JM. Screening and genetic diagnosis of haemoglobin disorders. Blood Rev. 17(1), 43-53 (2003).
3. Galanello R, Origa R. β-thalassemia. Orphanet J. Rare Dis. 5, 11 (2010).
4. Colah R, Gorakshakar A, Nadkarni A. Global burden, distribution and prevention of β-thalassemias and hemoglobin E disorders. Expert Rev. Hematol. 3(1), 103-117 (2010).
5. Quek L, Thein SL. Molecular therapies in β-thalassaemia. Br. J. Haematol. 136(3), 353-365 (2007).
6. Lederer CW, Basak AN, Aydinok Y et al. An electronic infrastructure for research and treatment of the thalassemias and other hemoglobinopathies: the Euro-mediterranean ITHANET project. Hemoglobin 33(3), 163-176 (2009).
7. Gambari R, Fibach E. Medicinal chemistry of fetal hemoglobin inducers for treatment of β-thalassemia. Curr. Med. Chem. 14(2), 199-212 (2007).
8. Testa U. Fetal hemoglobin chemical inducers for treatment of hemoglobinopa-thies. Ann. Hematol. 88(6), 505-528 (2009).
9. Voon HP, Wardan H, Vadolas J. Co-inheritance of α-and β-thalassaemia in mice ameliorates thalassaemic phenotype. Blood Cells Mol. Dis. 39 (2), 184-188 (2007).
10. Voon HP, Vadolas J. Controlling α-globin: a review of α-globin expression and its impact on β-thalassemia. Haematologica 93(12), 1868-1876 (2008).
11. Steinberg MH. Sicke cell disease and other hemoglobinopathies. In: Goldman's Cecil Medicine. Elsevier, 1066-1075 (2011).
12. Weatherall DJ. The thalassemias: disorders of globin synthesis. In: Williams Hematology. Prchal KK, Lichtman MA, Kipps TJ, Seligsohn U (Eds). McGraw-Hill, NY, USA (2010).
13. Dong A, Rivella S, Breda L. Gene therapy for hemoglobinopathies: progress and challenges. Transl. Res. 161(4), 293-306 (2013).
14. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with thalassaemia major. Pediatr. Endocrinol. Rev. 5(2), 642-648 (2007).
15. Tuck SM. Fertility and pregnancy in thalassemia major. Ann. NY Acad. Sci. 1054, 300-307 (2005).
16. Skordis N, Kyriakou A. The multifactorial origin of growth failure in thalassaemia. Pediatr. Endocrinol. Rev. 8(Suppl. 2), 271-277 (2011).
17. Sanctis D. Growth and puberty and its management in thalassaemia. Horm. Res. 58(Suppl. 1), 72-79 (2002).
18. Borgna-Pignatti C, Gamberini MR. Complications of thalassemia major and their treatment. Expert Rev. Hematol. 4(3), 353-366 (2011).
19. De Sanctis V, Gamberini MR, Borgatti L, Atti G, Vullo C, Bagni B. α and β cell evaluation in patients with thalassaemia intermedia and iron overload. Postgrad. Med. J. 61(721), 963-967 (1985).
20. Di Marco V, Bronte F, Cabibi D et al. Noninvasive assessment of liver fbrosis in thalassaemia major patients by transient elastography (TE)-lack of interference by iron deposition. Br. J. Haematol. 148 (3), 476-479 (2010).
21. Cunningham MJ. Update on thalassemia: clinical care and complications. Hematol. Oncol. Clin. North Am. 24(1), 215-227 (2010).
22. Bank A. On the road to gene therapy for β-thalassemia and sickle cell anemia. Pediatr. Hematol. Oncol. 25(1), 1-4 (2008).
23. Lisowski L, Sadelain M. Current status of globin gene therapy for the treatment of β-thalassaemia. Br. J. Haematol. 141(3), 335-345 (2008).
24. Breda L, Gambari R, Rivella S. Gene therapy in thalassemia and hemoglobino-pathies. Mediterr. J. Hematol. Infect. Dis. 1(1), e2009008 (2009).
25. Persons DA. Gene therapy: targeting β-thalassaemia. Nature 467(7313), 277-278 (2010).
26. Bank A. Hemoglobin gene therapy for β-thalassemia. Hematol. Oncol. Clin. North Am. 24(6), 1187-1201 (2010).
27. Boulad F, Rivière I, Sadelain M. Gene therapy for homozygous β-thalassemia. Is it a reality? Hemoglobin 33(Suppl. 1), S188-S196 (2009).
28. Yannaki E, Emery DW, Stamatoyannopou-los G. Gene therapy for β-thalassaemia: the continuing challenge. Expert Rev. Mol. Med. 12, e31 (2010).
29. Maina N, Zhong L, Li X et al. Optimization of recombinant adeno-associated viral vectors for human β-globin gene transfer and transgene expression. Hum. Gene Ther. 19(4), 365-375 (2008).
30. Gelinas R, Novak U. Retroviral vectors for the β-globin gene that demonstrate improved titer and expression. Ann. NY Acad. Sci. 612, 427-441 (1990).
31. Dong WJ, Li B, Liu DP et al. Evaluation of optimal expression cassette in retrovirus vector for β-thalassemia gene therapy. Mol. Biotechnol. 24(2), 127-140 (2003).
32. Yi Y, Noh MJ, Lee KH. Current advances in retroviral gene therapy. Curr. Gene Ther. 11(3), 218-228 (2011).
33. Sadelain M, Rivella S, Lisowski L, Samakoglu S, Rivière I. Globin gene transfer for treatment of the β-thalassemias and sickle cell disease. Best Pract. Res. Clin. Haematol. 17(3), 517-534 (2004).
34. Case SS, Price MA, Jordan CT et al. Stable transduction of quiescent CD34+CD38-human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. Natl Acad. Sci. USA 96(6), 2988-2993 (1999).
35. Lisowski L, Sadelain M. Locus control region elements HS1 and HS4 enhance the therapeutic effcacy of globin gene transfer in β-thalassemic mice. Blood 110(13), 4175-4178 (2007).
36. Hargrove PW, Kepes S, Hanawa H et al. Globin lentiviral vector insertions can perturb the expression of endogenous genes in β-thalassemic hematopoietic cells. Mol. Ther. 16(3), 525-533 (2008).
37. Zhou HS, Zhao N, Li L et al. Site-specifc transfer of an intact β-globin gene cluster through a new targeting vector. Biochem. Biophys. Res. Commun. 356(1), 32-37 (2007).
38. Zhao S, Weinreich MA, Ihara K, Richard RE, Blau CA. In vivo selection of genetically modifed erythroid cells using a jak2-based cell growth switch. Mol. Ther. 10(3), 456-468 (2004).
39. Persons DA. The challenge of obtaining therapeutic levels of genetically modifed hematopoietic stem cells in β-thalassemia patients. Ann. NY Acad. Sci. 1202, 69-74 (2010).
40. Yannaki E, Psatha N, Athanasiou E et al. Mobilization of hematopoietic stem cells in a thalassemic mouse model: implications for human gene therapy of thalassemia. Hum. Gene Ther. 21(3), 299-310 (2010).
41. Yannaki E, Stamatoyannopoulos G. Hematopoietic stem cell mobilization strategies for gene therapy of β thalassemia and sickle cell disease. Ann. NY Acad. Sci. 1202, 59-63 (2010).
42. Kumar P, Woon-Khiong C. Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications. Curr. Gene Ther. 11 (2), 144-153 (2011).
43. Miccio A, Cesari R, Lotti F et al. In vivo selection of genetically modifed erythro-blastic progenitors leads to long-term correction of β-thalassemia. Proc. Natl Acad. Sci. USA 105(30), 10547-10552 (2008).
44. Negre O, Fusil F, Colomb C et al. Correction of murine β-thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid expansion. Blood 117(20), 5321-5331 (2011).
45. Persons DA, Allay ER, Sawai N et al. Successful treatment of murine β-thalassemia using in vivo selection of genetically modifed, drug-resistant hematopoietic stem cells. Blood 102(2), 506-513 (2003).
46. Imren S, Payen E, Westerman KA et al. Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc. Natl Acad. Sci. USA 99(22), 14380-14385 (2002).
47. May C, Rivella S, Callegari J et al. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin. Nature 406(6791), 82-86 (2000).
48. May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene. Blood 99(6), 1902-1908 (2002).
49. Puthenveetil G, Scholes J, Carbonell D et al. Successful correction of the human β-thalassemia major phenotype using a lentiviral vector. Blood 104 (12), 3445-3453 (2004).
50. Wilber A, Hargrove PW, Kim YS et al. Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. Blood 117(10), 2817-2826 (2011).
51. Imren S, Fabry ME, Westerman KA et al. High-level β-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. J. Clin. Invest. 114 (7), 953-962 (2004).
52. Tisdale J, Sadelain M. Toward gene therapy for disorders of globin synthesis. Semin. Hematol. 38(4), 382-392 (2001).
53. Kafri T. Lentivirus vectors: diffculties and hopes before clinical trials. Curr. Opin. Mol. Ther. 3(4), 316-326 (2001).
54. Arumugam PI, Urbinati F, Velu CS, Higashimoto T, Grimes HL, Malik P. The 3′ region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS ONE 4(9), e6995 (2009).
55. Bank A, Dorazio R, Leboulch P. A Phase I/II clinical trial of β-globin gene therapy for β-thalassemia. Ann. NY Acad. Sci. 1054, 308-316 (2005).
56. Breda L, Kleinert DA, Casu C et al. A preclinical approach for gene therapy of β-thalassemia. Ann. NY Acad. Sci. 1202, 134-140 (2010).
57. Sadelain M, Rivière I, Wang X et al. Strategy for a multicenter Phase I clinical trial to evaluate globin gene transfer in β-thalassemia. Ann. NY Acad. Sci. 1202, 52-58 (2010).
58. Giardini C, Lucarelli G. Bone marrow transplantation in the treatment of thalassemia. Curr. Opin. Hematol. 1(2), 170-176 (1994).
59. Bender MA, Gelinas RE, Miller AD. A majority of mice show long-term expression of a human β-globin gene after retrovirus transfer into hematopoietic stem cells. Mol. Cell. Biol. 9 (4), 1426-1434 (1989).
60. Dzierzak EA, Papayannopoulou T, Mulligan RC. Lineage-specifc expression of a human β-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 331(6151), 35-41 (1988).
61. Karlsson S, Bodine DM, Perry L, Papayannopoulou T, Nienhuis AW. Expression of the human β-globin gene following retroviral-mediated transfer into multipotential hematopoietic progenitors of mice. Proc. Natl Acad. Sci. USA 85(16), 6062-6066 (1988).
62. Lung HY, Meeus IS, Weinberg RS, Atweh GF. In vivo silencing of the human γ-globin gene in murine erythroid cells following retroviral transduction. Blood Cells Mol. Dis. 26 (6), 613-619 (2000).
63. Chang JC, Liu D, Kan YW. A 36-base-pair core sequence of locus control region enhances retrovirally transferred human β-globin gene expression. Proc. Natl Acad. Sci. USA 89(7), 3107-3110 (1992).
64. Plavec I, Papayannopoulou T, Maury C, Meyer F. A human β-globin gene fused to the human β-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells. Blood 81(5), 1384-1392 (1993).
65. Emery DW, Morrish F, Li Q, Stamatoyan-nopoulos G. Analysis of γ-globin expression cassettes in retrovirus vectors. Hum. Gene Ther. 10(6), 877-888 (1999).
66. Fragkos M, Anagnou NP, Tubb J, Emery DW. Use of the hereditary persistence of fetal hemoglobin 2 enhancer to increase the expression of oncoretrovirus vectors for human y-globin. Gene Ther. 12(21), 1591-1600 (2005).
67. Kalberer CP, Pawliuk R, Imren S et al. Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human ß-globin in engrafted mice. Proc. Natl Acad. Sci. USA 97(10), 5411-5415 (2000).
68. Han XD, Lin C, Chang J, Sadelain M, Kan YW. Fetal gene therapy of (X-thalassemia in a mouse model. Proc. Natl Acad. Sci. USA 104(21), 9007-9011 (2007).
69. Rivella S, May C, Chadburn A, Rivière I, Sadelain M. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human ß-globin gene transfer. Blood 101(8), 2932-2939 (2003).
70. Pawliuk R, Westerman KA, Fabry ME et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294(5550), 2368-2371 (2001).
71. Samakoglu S, Lisowski L, Budak-Alpdogan T et al. A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat. Biotechnol. 24(1), 89-94 (2006).
72. Miccio A, Poletti V, Tiboni F et al. The GATA1-HS2 enhancer allows persistent and position-independent expression of a ß-globin transgene. PLoS ONE 6(12), e27955 (2011).
73. Breda L, Casu C, Gardenghi S et al Therapeutic hemoglobin levels after gene transfer in ß-thalassemia mice and in hematopoietic cells of ß-thalassemia and sickle cells disease patients. PLoS ONE 7(3), e32345 (2012).
74. Arumugam PI, Higashimoto T, Urbinati F et al. Genotoxic potential of lineage-specifc lentivirus vectors carrying the ß-globin locus control region. Mol. Ther. 17(11), 1929-1937 (2009).
75. Rivella S, Callegari JA, May C, Tan CW, Sadelain M. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J. Virol. 74(10), 4679-4687 (2000).
76. Arumugam P, Malik P. Genetic therapy for ß-thalassemia: from the bench to the bedside. Hematology Am. Soc. Hematol. Educ. Program 2010, 445-450 (2010).
77. Cavazzana-Calvo M, Payen E, Negre O et al. Transfusion independence and HMGA2 activation after gene therapy of human ß-thalassaemia. Nature 467(7313), 318-322 (2010).
78. Kaiser J. Gene therapy. β-thalassemia treatment succeeds, with a caveat. Science 326 (5959), 1468-1469 (2009).
79. Ronen K, Negre O, Roth S et al. Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat β-thalassemia. Mol. Ther. 19 (7), 1273-1286 (2011).
80. Cao A, Galanello R. β-thalassemia. Genet. Med. 12(2), 61-76 (2010).
81. Cao A, Moi P, Galanello R. Recent advances in β-thalassemias. Pediatr. Rep. 3(2), e17 (2011).
82. Gambari R. Foetal haemoglobin inducers and thalassaemia: novel achievements. Blood Transfus. 8(1), 5-7 (2010).
83. Bianchi N, Zuccato C, Lampronti I, Borgatti M, Gambari R. Fetal hemoglobin inducers from the natural world: a novel approach for identifcation of drugs for the treatment of β-thalassemia and sickle-cell anemia. Evid. Based. Complement. Alternat. Med. 6(2), 141-151 (2009).
84. Feriotto G, Salvatori F, Finotti A et al. A novel frameshift mutation (+A) at codon 18 of the β-globin gene associated with high persistence of fetal hemoglobin phenotype and Δβ-thalassemia. Acta Haematol. 119(1), 28-37 (2008).
85. Zhao H, Pestina TI, Nasimuzzaman M, Mehta P, Hargrove PW, Persons DA. Amelioration of murine β-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both γ-globin and the MGMT drug-resistance gene. Blood 113(23), 5747-5756 (2009).
86. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for β-thalassaemia: a review of international practice. Eur. J. Hum. Genet. 18 (10), 1077-1083 (2010).
87. Moutouh-De Parseval LA, Verhelle D, Glezer E et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J. Clin. Invest. 118(1), 248-258 (2008).
88. Boosalis MS, Castaneda SA, Trudel M et al. Novel therapeutic candidates, identifed by molecular modeling, induce γ-globin gene expression in vivo. Blood Cells Mol. Dis. 47 (2), 107-116 (2011).
89. Italia KY, Jijina FJ, Merchant R et al. Response to hydroxyurea in β thalassemia major and intermedia: experience in western India. Clin. Chim. Acta 407(1-2), 10-15 (2009).
90. Ehsani MA, Hedayati-Asl AA, Bagheri A, Zeinali S, Rashidi A. Hydroxyurea-induced hematological response in transfusion-independent β-thalassemia intermedia: case series and review of literature. Pediatr. Hematol. Oncol. 26(8), 560-565 (2009).
91. Masera N, Tavecchia L, Capra M et al. Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. Blood Transfus. 8(1), 63-65 (2010).
92. Aguilar-Lopez LB, Delgado-Lamas JL, Rubio-Jurado B, Perea FJ, Ibarra B. Thalidomide therapy in a patient with thalassemia major. Blood Cells Mol. Dis. 41(1), 136-137 (2008).
93. Emery DW, Yannaki E, Tubb J, Nishino T, Li Q, Stamatoyannopoulos G. Development of virus vectors for gene therapy of β chain hemoglobinopathies: fanking with a chromatin insulator reduces γ-globin gene silencing in vivo. Blood 100(6), 2012-2019 (2002).
94. Hanawa H, Hargrove PW, Kepes S, Srivastava DK, Nienhuis AW, Persons DA. Extended β-globin locus control region elements promote consistent therapeutic expression of a γ-globin lentiviral vector in murine β-thalassemia. Blood 104 (8), 2281-2290 (2004).
95. Persons DA, Hargrove PW, Allay ER, Hanawa H, Nienhuis AW. The degree of phenotypic correction of murine β-thalassemia intermedia following lentiviral-mediated transfer of a human γ-globin gene is infuenced by chromosomal position effects and vector copy number. Blood 101(6), 2175-2183 (2003).
96. Nishino T, Tubb J, Emery DW. Partial correction of murine β-thalassemia with a γ retrovirus vector for human γ-globin. Blood Cells Mol. Dis. 37(1), 1-7 (2006).
97. Nishino T, Cao H, Stamatoyannopoulos G, Emery DW. Effects of human γ-globin in murine β-thalassaemia. Br. J. Haematol. 134(1), 100-108 (2006).
98. Thein SL, Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Br. J. Haematol. 145(4), 455-467 (2009).
99. Forget BG. Progress in understanding the hemoglobin switch. N. Engl. J. Med. 365(9), 852-854 (2011).
100. Sankaran VG, Xu J, Byron R et al. A functional element necessary for fetal hemoglobin silencing. N. Engl. J. Med. 365(9), 807-814 (2011).
101. Galanello R. Recent advances in the molecular understanding of non-transfusion-dependent thalassemia. Blood Rev. 26(Suppl. 1), S7-S11 (2012).
102. Xu XS, Hong X, Wang G. Induction of endogenous γ-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence. J. Hematol. Oncol. 2, 15 (2009).
103. Jiang J, Best S, Menzel S et al. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood 108 (3), 1077-1083 (2006).
104. Sankaran VG, Menne TF, Xu J et al. Human fetal hemoglobin expression is regulated by the developmental stage-specifc repressor BCL11A. Science 322(5909), 1839-1842 (2008).
105. Sankaran VG, Xu J, Orkin SH. Transcrip-tional silencing of fetal hemoglobin by BCL11A. Ann. NY Acad. Sci. 1202, 64-68 (2010).
106. Sankaran VG. Targeted therapeutic strategies for fetal hemoglobin induction. Hematology Am. Soc. Hematol. Educ. Program 2011, 459-465 (2011).
107. Nguyen TK, Joly P, Bardel C, Moulsma M, Bonello-Palot N, Francina A. The XmnI (G)γ polymorphism infuences hemoglobin F synthesis contrary to BCL11A and HBS1L-MYB SNPs in a cohort of 57 β-thalassemia intermedia patients. Blood Cells Mol. Dis. 45(2), 124-127 (2010).
108. Bianchi NFG, Gambari R, Mischiati C. Synthetic oligonucleotides as inducers of erythroid differentiation. PCT/EP01/02804 (2001).
109. Sankaran VG, Menne TF, Scepanovic D et al. MicroRNA-15a and-16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc. Natl Acad. Sci. USA 108 (4), 1519-1524 (2011).
110. Zhou D, Liu K, Sun CW, Pawlik KM, Townes TM. KLF1 regulates BCL11A expression and γ-to β-globin gene switching. Nat. Genet. 42 (9), 742-744 (2010).
111. Gräslund T, Li X, Magnenat L, Popkov M, Barbas CF 3rd. Exploring strategies for the design of artifcial transcription factors: targeting sites proximal to known regulatory regions for the induction of γ-globin expression and the treatment of sickle cell disease. J. Biol. Chem. 280(5), 3707-3714 (2005).
112. Wilber A, Tschulena U, Hargrove PW et al. A zinc-fnger transcriptional activator designed to interact with the γ-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts. Blood 115(15), 3033-3041 (2010).
113. Zhu J, Chin K, Aerbajinai W, Trainor C, Gao P, Rodgers GP. Recombinant erythroid Kruppel-like factor fused to GATA1 up-regulates Δ-and γ-globin expression in erythroid cells. Blood 117 (11), 3045-3052 (2011).
114. Musallam KM, Sankaran VG, Cappellini MD, Duca L, Nathan DG, Taher AT. Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood 119(2), 364-367 (2012).
115. Zuccato C, Breda L, Salvatori F et al. A combined approach for β-thalassemia based on gene therapy-mediated adult hemoglobin (HbA) production and fetal hemoglobin (HbF) induction. Ann. Hematol. 91(8), 1201-1213 (2012).
116. Lampronti I, Bianchi N, Zuccato C et al. Increase in γ-globin mRNA content in human erythroid cells treated with angelicin analogs. Int. J. Hematol. 90(3), 318-327 (2009).
117. Macari ER, Lowrey CH. Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway. Blood 117(22), 5987-5997 (2011).
118. Olivieri NF, Saunthararajah Y, Thayalasuthan V et al.; Thalassemia Clinical Research Network. A pilot study of subcutaneous decitabine in β-thalassemia intermedia. Blood 118 (10), 2708-2711 (2011).